...
首页> 外文期刊>Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract >Inhaled Beta Agonist Bronchodilator Does Not Affect Trans-diaphragmatic Pressure Gradient but Decreases Lower Esophageal Sphincter Retention Pressure in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Gastroesophageal Reflux Disease (GERD)
【24h】

Inhaled Beta Agonist Bronchodilator Does Not Affect Trans-diaphragmatic Pressure Gradient but Decreases Lower Esophageal Sphincter Retention Pressure in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Gastroesophageal Reflux Disease (GERD)

机译:吸入的β激动剂支气管扩张剂不影响逆膈压力梯度,但减少慢性阻塞性肺病(COPD)和胃食管反流疾病(GERD)患者的食管括约肌保留压力较低

获取原文
获取原文并翻译 | 示例
           

摘要

Background Chronic obstructive pulmonary disease (COPD) patients have a high incidence of gastroesophageal reflux disease (GERD) whose pathophysiology seems to be linked to an increased trans-diaphragmatic pressure gradient and not to a defective esophagogastric barrier. Inhaled beta agonist bronchodilators are a common therapy used by patients with COPD. This drug knowingly not only leads to a decrease in the lower esophageal sphincter (LES) resting pressure, favoring GERD, but also may improve ventilatory parameters, therefore preventing GERD.
机译:背景技术慢性阻塞性肺疾病(COPD)患者具有高胃食管反流疾病(GERD)的发病率,其病理生理学似乎与增加的反膜膜压力梯度有关,而不是缺陷的食管痛障碍。 吸入的β激动剂支气管扩张剂是COPD患者使用的常见疗法。 这种药物不仅导致较低的食管括约肌(LES)静息压力下降,有利于GERD,也可以改善通风参数,因此可以防止凸起。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号